AssetMark Inc’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

AssetMark Inc’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1	Closed	–	–	1470
2016 Q4	$0	Buy	+1	New	+$113	﹤0.01%	1408

Other funds holding LUMO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AssetMark Inc's LUMO Position: Q1 2017 in Review

AssetMark Inc sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2017, closing a stake of 1 share.

AssetMark Inc first reported a position in LUMO in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 128 funds tracked by Wall St. Rank hold LUMO as of Q1 2017.

AssetMark Inc reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
AssetMark Inc sold 1 Lumos Pharma, Inc. Common Stock share in Q1 2017.
AssetMark Inc first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
AssetMark Inc's Lumos Pharma, Inc. Common Stock position peaked at $0 in Q4 2016.
128 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2017.

Based on AssetMark Inc's 13F filing for Q1 2017, filed 9 May 2017.